Therapeutic inhibition of excessive lung inflammation induced by anti-SARS-CoV-2 antibodies

Project description In critically ill COVID-19 patients, pneumonia is associated with very strong inflammatory reactions, which can lead to multiple organ failure and eventual death. The current treatment options for the critically ill COVID-19 patients are unfortunately limited. Since the development and distribution of a vaccine will take one to two years, there is an urgent need for treatment for this category of most ill patients. Research and expected outcomes This study will investigate the underlying reason for these severe inflammatory reactions and will test which possible treatment options (drugs) can counteract these extreme inflammatory reactions. The findings indicate that critically ill COVID-19 patients produce a different kind of antibody against the virus, which in turn triggers the extreme inflammatory response. This could explain why this group of patients deteriorates so much after about a week and a half.